Aimmune Therapeuticsincis A Clinical Stage Biopharmaceutical Company Dedicated To Developing And Commercializing Treatments For Life Threatening Food Allergiesfounded In 2011Aimmune Operates As A Subsidiary Of Socia Tades Produits Nestlas Aunder Nestlahealth Sciencethe Company Collaborates With Food Allergy Research & Educationfareto Advance Its Mission Aimmune S Primary Focus Is On Standardized Desensitization Drug Products And Protocolsits Lead Productpalforziaar 101 Is An Fda Approved Treatment For Peanut Allergyutilizing The Proprietary Characterized Oral Desensitization Immunotherapycoditapproachthis Method Aims To Protect Patients From Allergic Reactions By Desensitizing Them To Specific Allergensaimmune Is Also Developing Investigational Therapies For Other Food Allergiesincluding Egg And Cowae S Milkwhile Engaging In Research For Gastrointestinal And Metabolic Related Diseases Headquartered In Brisbanecaliforniaaimmune Has Additional Offices In Durhamnorth Carolinalondonenglanddublinirelandand Munichgermanythe Company Partners With Leading Biotechnology Firms To Enhance Its Research And Development Efforts
